Medicine put to the test

The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient for derivation of an added benefit

2020-01-15 The small studies on the histology-independent use of the inhibitor have no controls. The amount of other data is also still too small to assess an added benefit.

read more Link to \Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient for derivation of an added benefit\""

Asfotase alfa in hypophosphatasia in childhood and adolescence: survival benefit for infants

2020-01-15 More infants survive congenital metabolic disorder under enzyme replacement therapy. Due to lack of data it is unclear whether older children, adolescents and adults also benefit.

read more Link to \Asfotase alfa in hypophosphatasia in childhood and adolescence: survival benefit for infants\""

An appeal for independent research and decision-making: How to produce trustworthy evidence for healthcare decisions without commercial interference

2019-12-05 We all want to base our healthcare decisions on trustworthy evidence. But often enough, financial ties between the pharmaceutical and medical devices industry and healthcare players lead to bias in th…

read more Link to \An appeal for independent research and decision-making: How to produce trustworthy evidence for healthcare decisions without commercial interference\""

Advanced heart failure: telemonitoring reduces cardiovascular mortality

2019-10-28 If patients are actively involved in telemonitoring, all-cause mortality is also lower – as long as they do not show depressive symptoms.

read more Link to \Advanced heart failure: telemonitoring reduces cardiovascular mortality\""

Liver transplantations: Better results with larger case numbers

2019-10-02 In hospitals with many liver transplantations, the chances of survival are higher. However, there are no studies on the effects of specific minimum case numbers introduced into health care.

read more Link to \Liver transplantations: Better results with larger case numbers\""

Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations

2019-09-19 After a methodological uncertainty has been resolved, the analyses on overall survival are now usable. Two addenda now show an added benefit for specific patients.

read more Link to \Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations\""

Newborn screening for sickle cell disease can prevent deaths

2019-09-19 Earlier diagnosis of sickle cell disease combined with prevention of infections and education of relatives increases the life expectancy of affected children.

read more Link to \Newborn screening for sickle cell disease can prevent deaths\""

Biologics in rheumatoid arthritis: better evidence, but direct comparisons still lacking

2019-09-17 Studies on biologics are too short and too often include placebo controls – this hampers comparisons of biologics; however, due to new data provided by companies, new findings are available

read more Link to \Biologics in rheumatoid arthritis: better evidence, but direct comparisons still lacking\""

Current commenting procedures (Hearings)

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Ropeginterferon alfa-2b (Besremi) for the treatment of polycythemia vera

Ropeginterferon alfa-2b (trade name: Besremi) has been approved in Germany since February 2019 for the treatment of polycythemia vera (PV) in adults. It is an option for patients whose spleen has not yet become so enlarged that it causes problems.   read more (Link to \Ropeginterferon alfa-2b (Besremi) for the treatment of polycythemia vera\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close